CRIS - Curis Inc Stock Price, Fair Value and News

11.80USD-0.80 (-6.35%)Delayed

Market Summary

USD11.80-0.80

Delayed

-6.35%

CRIS Stock Price

View Fullscreen

CRIS RSI Chart

CRIS Valuation

Market Cap

69.6M

Price/Earnings (Trailing)

-1.46

Price/Sales (Trailing)

7.09

Price/Free Cashflow

-1.76

CRIS Price/Sales (Trailing)

CRIS Profitability

Return on Equity

-504.44%

Return on Assets

-76.95%

Free Cashflow Yield

-56.7%

CRIS Fundamentals

CRIS Revenue

Revenue (TTM)

9.8M

Rev. Growth (Yr)

-9.19%

Rev. Growth (Qtr)

-22.63%

CRIS Earnings

Earnings (TTM)

-47.7M

Earnings Growth (Yr)

-2.74%

Earnings Growth (Qtr)

-1.4%

Breaking Down CRIS Revenue

Last 7 days

-24.9%

Last 30 days

-26.0%

Last 90 days

12.5%

Trailing 12 Months

1288.2%

How does CRIS drawdown profile look like?

CRIS Financial Health

Current Ratio

4.08

CRIS Investor Care

Shares Dilution (1Y)

22.01%

Diluted EPS (TTM)

-8.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	9.8M	0	0	0
2023	10.4M	10.2M	10.2M	10.0M
2022	10.5M	10.6M	10.4M	10.2M
2021	10.3M	10.2M	10.5M	10.6M
2020	10.9M	11.2M	11.1M	10.8M
2019	9.7M	9.5M	9.5M	10.0M
2018	10.2M	10.5M	10.9M	10.4M
2017	7.9M	8.3M	9.0M	9.9M
2016	7.9M	7.5M	7.3M	7.5M
2015	10.2M	7.5M	7.8M	7.9M
2014	15.4M	14.8M	9.4M	9.8M
2013	7.5M	8.5M	15.2M	15.0M
2012	19.6M	24.5M	29.4M	17.0M
2011	15.7M	15.4M	15.1M	14.8M
2010	0	11.1M	13.5M	16.0M
2009	0	0	0	8.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Curis Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 31, 2022	dentzer james e	sold	-9,498	3.07	-3,094	president & ceo
Jan 27, 2022	dentzer james e	sold	-7,651	3.18	-2,406	president & ceo
Jan 26, 2021	dentzer james e	sold	-32,758	10.5876	-3,094	president & ceo
Jan 25, 2021	dentzer james e	sold	-25,021	10.96	-2,283	president & ceo
Jan 24, 2020	dentzer james e	sold	-5,076	1.6407	-3,094	president & ceo
Jan 23, 2020	dentzer james e	sold	-6,181	1.6899	-3,658	president & ceo
Jan 24, 2019	dentzer james e	sold	-3,576	1.1561	-3,094	president & ceo
Jan 23, 2019	greenacre martyn d	sold	-19,474	1.0527	-18,500	-
Jan 23, 2019	kaitin kenneth i	sold	-15,587	1.0532	-14,800	-
Jan 23, 2019	dentzer james e	sold	-2,612	1.09	-2,397	president & ceo

Which funds bought or sold CRIS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	unchanged	-	-188	1,087	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-39,572	228,803	-%
May 15, 2024	MORGAN STANLEY	reduced	-0.56	-1,734	9,664	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	100	28.00	66.00	-%
May 15, 2024	LM Advisors LLC	sold off	-100	-2,550	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	8,436	10,067	10,207	-%
May 15, 2024	Royal Bank of Canada	added	155	1,000	4,000	-%
May 15, 2024	KINGDON CAPITAL MANAGEMENT, L.L.C.	reduced	-50.00	-4,157,120	3,088,710	0.34%
May 15, 2024	Point72 Asset Management, L.P.	new	-	131,527	131,527	-%
May 15, 2024	MAVERICK CAPITAL LTD	unchanged	-	-1,094,670	6,329,310	0.12%

Are Funds Buying or Selling CRIS?

Are funds buying CRIS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CRIS

No. of Funds

Unveiling Curis Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 15, 2024	kingdon capital management, l.l.c.	5.9%	345,730	SC 13G
Feb 14, 2024	maverick capital ltd	9.9%	582,273	SC 13G/A
Feb 12, 2024	m28 capital management lp	7.2%	421,951	SC 13G
Feb 14, 2023	maverick capital ltd	5.8%	5,555,598	SC 13G/A
Jan 20, 2023	state street corp	0.26%	255,009	SC 13G/A
Jul 08, 2022	blackrock inc.	2.6%	2,359,787	SC 13G
Feb 14, 2022	point72 asset management, l.p.	1.6%	1,442,543	SC 13G/A
Feb 14, 2022	maverick capital ltd	8.5%	7,790,478	SC 13G
Feb 11, 2022	state street corp	8.51%	7,799,328	SC 13G
Feb 04, 2022	blackrock inc.	6.9%	6,281,041	SC 13G

Recent SEC filings of Curis Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 07, 2024	8-K	Current Report
May 07, 2024	10-Q	Quarterly Report
Apr 15, 2024	SC 13G	Major Ownership Report
Apr 12, 2024	EFFECT	EFFECT
Apr 10, 2024	DEFA14A	DEFA14A
Apr 10, 2024	DEF 14A	DEF 14A
Apr 10, 2024	ARS	ARS
Apr 10, 2024	CORRESP	CORRESP
Mar 29, 2024	PRE 14A	PRE 14A

Peers (Alternatives to Curis Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Curis Inc News

Latest updates

Curis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-22.6%	2,086	2,696	2,833	2,197	2,297	2,887	2,825	2,393	2,057	3,135	3,039	2,286	2,189	3,024	2,742	2,360	2,709	3,287	2,856	2,094	1,767
Costs and Expenses	-2.3%	14,555	14,895	15,201	14,335	13,924	13,107	15,431	17,454	17,190	15,702	13,087	12,936	10,989	9,299	7,453	7,790	11,191	10,621	8,179	8,235	7,325
S&GA Expenses	-100.0%	-	4,877	4,761	4,249	4,760	4,330	4,556	5,089	5,673	4,773	4,334	4,067	4,123	3,539	2,613	2,386	3,593	2,999	2,887	2,526	3,143
Interest Expenses	-100.0%	-	182	753	763	661	1,019	1,002	1,017	1,074	1,080	1,052	1,112	1,193	-2,443	-	-	1,062	-	-	-	791
Net Income	-1.4%	-11,876	-11,712	-12,181	-11,961	-11,559	-11,329	-13,294	-15,940	-16,109	-13,620	-11,051	-10,838	-9,927	-7,517	-5,974	-6,708	-9,709	-8,609	-6,436	-7,213	-9,884
Net Income Margin	-2.8%	-4.86*	-4.73*	-4.60*	-4.72*	-5.01*	-5.58*	-5.66*	-5.34*	-4.91*	-4.27*	-3.73*	-3.34*	-	-	-	-	-	-	-	-	-
Free Cashflow	-29.6%	-13,200	-10,186	-8,181	-7,868	-12,199	-12,268	-13,174	-12,485	-16,826	-8,171	-9,610	-6,659	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-19.7%	62.00	77.00	90.00	84.00	95.00	109	123	129	141	162	172	181	191	204	46.00	45.00	27.00	35.00	42.00	48.00	55.00
Current Assets	-24.4%	46.00	61.00	73.00	68.00	78.00	92.00	106	113	126	122	135	157	162	173	28.00	27.00	17.00	25.00	33.00	38.00	45.00
Cash Equivalents	14.3%	31.00	27.00	24.00	20.00	32.00	20.00	30.00	35.00	19.00	41.00	54.00	76.00	112	130	24.00	25.00	14.00	16.00	21.00	27.00	43.00
Net PPE	-14.7%	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
Goodwill	-0.2%	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00
Liabilities	-8.8%	53.00	58.00	60.00	58.00	58.00	62.00	67.00	67.00	65.00	72.00	69.00	69.00	69.00	74.00	74.00	75.00	67.00	69.00	68.00	69.00	69.00
Current Liabilities	-16.4%	11.00	14.00	14.00	10.00	8.00	10.00	14.00	12.00	10.00	13.00	9.00	8.00	7.00	10.00	9.00	9.00	6.00	7.00	5.00	4.00	5.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	1.00	0.00	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	0.00	0.00	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	1.00	0.00	-	-	-	-	-
Shareholder's Equity	-51.9%	9.00	20.00	30.00	26.00	37.00	47.00	56.00	62.00	76.00	91.00	103	112	122	131	-	-	-	-	-	-	-
Retained Earnings	-0.7%	-1,208	-1,200	-1,184	-1,172	-1,160	-1,149	-1,137	-1,124	-1,100	-1,092	-1,100	-1,067	-1,056	-1,046	-1,039	-1,000	-1,000	-1,016	-1,008	-1,000	-994
Additional Paid-In Capital	0.1%	1,217	1,216	1,214	1,198	1,196	1,196	1,193	1,186	1,184	1,182	1,181	1,179	1,178	1,177	1,010	1,003	986	983	982	981	981
Shares Outstanding	0%	6.00	6.00	6.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	82.00	-	-	-	90.00	-	-	-	737	-	-	-	54.00	-	-	-	51.00	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-29.6%	-13,200	-10,186	-8,181	-7,868	-12,199	-12,268	-13,122	-12,132	-16,815	-8,171	-9,610	-6,659	-13,179	-5,715	-5,877	-5,131	-9,016	-5,599	-6,704	-6,669	-7,233
Share Based Compensation	0.7%	1,559	1,548	1,633	1,424	1,395	1,744	1,324	1,966	1,718	1,441	1,464	1,275	1,099	865	623	585	625	692	684	631	651
Cashflow From Investing	30.3%	18,913	14,517	180	-3,154	26,243	3,463	4,303	28,340	-3,083	-3,523	-11,530	-28,771	-4,071	-53,469	-162	-258	4,841	1,549	1,453	-8,058	600
Cashflow From Financing	-13.6%	-2,406	-2,118	12,556	-852	-2,006	-1,388	4,662	-759	-1,648	-1,312	-956	-575	-1,329	165,239	5,820	16,478	1,277	-1,061	-611	-820	25,763

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CRIS Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues, net	$ 2,086	$ 2,297
Operating expenses:
Cost of royalties	47	24
Research and development	9,617	9,140
General and administrative	4,891	4,760
Total operating expenses	14,555	13,924
Loss from operations	(12,469)	(11,627)
Other income:
Interest income	515	652
Income (expense) related to the sale of future royalties	78	(584)
Total other income	593	68
Net loss	$ (11,876)	$ (11,559)
Net loss per common share (basic ) (in dollars per share)	$ (2.05)	$ (2.39)
Net loss per common share (diluted) (in dollars per share)	$ (2.05)	$ (2.39)
Weighted average common shares (basic) (in shares)	5,783,585	4,830,763
Weighted average common shares (diluted) (in shares)	5,783,585	4,830,763
Net loss	$ (11,876)	$ (11,559)
Other comprehensive income:
Unrealized gain on marketable securities	109	195
Comprehensive loss	$ (11,767)	$ (11,364)

CRIS Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 29,956	$ 26,681
Short-term investments	10,764	29,653
Accounts receivable	2,154	2,794
Prepaid expenses and other current assets	3,192	1,780
Total current assets	46,066	60,908
Property and equipment, net	370	434
Restricted cash, long-term	544	544
Operating lease right-of-use asset	2,704	3,056
Other assets	3,358	3,358
Goodwill	8,982	8,982
Total assets	62,024	77,282
Current liabilities:
Accounts payable	3,628	3,172
Accrued liabilities	6,326	9,040
Current portion of operating lease liability	1,349	1,305
Total current liabilities	11,303	13,517
Long-term operating lease liability	1,137	1,489
Liability related to the sale of future royalties, net	40,122	42,606
Total liabilities	52,562	57,612
Stockholders’ equity:
Preferred stock, $0.01 par value—5,000,000 shares authorized, no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.01 par value—22,781,250 shares authorized, 5,894,085 shares issued and outstanding at March 31, 2024 and December 31, 2023	59	59
Additional paid-in capital	1,217,351	1,215,792
Accumulated deficit	(1,208,286)	(1,196,410)
Accumulated other comprehensive gain	338	229
Total stockholders’ equity	9,462	19,670
Total liabilities and stockholders’ equity	$ 62,024	$ 77,282
Common stock issued (in shares)	5,894,085	5,894,085
Common stock outstanding (in shares)	5,894,085	5,894,085
Common stock authorized (in shares)	22,781,250	22,781,250

About Curis Inc

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with solid tumors and lymphomas; and CA-327, a pre-clinical development candidate, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma; and Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

CEO	Mr. James E. Dentzer
WEBSITE	curis.com
INDUSTRY	Biotechnology
EMPLOYEES	51

Curis Inc Frequently Asked Questions

What is the ticker symbol for Curis Inc? What does CRIS stand for in stocks?

CRIS is the stock ticker symbol of Curis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Curis Inc (CRIS)?

As of Fri May 17 2024, market cap of Curis Inc is 69.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRIS stock?

You can check CRIS's fair value in chart for subscribers.

What is the fair value of CRIS stock?

You can check CRIS's fair value in chart for subscribers. The fair value of Curis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Curis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRIS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Curis Inc a good stock to buy?

The fair value guage provides a quick view whether CRIS is over valued or under valued. Whether Curis Inc is cheap or expensive depends on the assumptions which impact Curis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRIS.

What is Curis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CRIS's PE ratio (Price to Earnings) is -1.46 and Price to Sales (PS) ratio is 7.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRIS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Curis Inc's stock?

In the past 10 years, Curis Inc has provided 0.028 (multiply by 100 for percentage) rate of return.